Prestige Biologics, a Contract Development and Manufacturing Organization (CDMO) specializing in biopharmaceuticals, has signed a biologics manufacturing deal with Celltrion, a developer of the world's first monoclonal antibody biosimilar.

The 5-year agreement will establish Prestige Biologics as a leading biologics manufacturing company in Osong, one of the biggest biomedical hubs in South Korea. This collaboration with Celltrion underscores Prestige Biologics' expertise in biopharmaceuticals, solidifying its prominent position in the rapidly evolving field of biologics manufacturing.

"We are pleased to announce our partnership with Celltrion,” stated Jae Young Yang, Director of the Business Development (BD) Center. “This contract holds a significant meaning as it marks the official beginning of Prestige Biologics’ CDMO business. This proven track record with Celltrion will pave the way for future contracts with global biologics clients.”

Prestige Biologics is a biopharmaceutical CDEMO (Contract Development Engineering and Manufacturing Organization) that operates production facilities based in South Korea. With a manufacturing capacity of 154,000 litres, Prestige Biologics stands as one of the top 10 global CDMO companies working with animal cell culture.

Celltrion is a leading biopharmaceutical company dedicated to developing innovative therapeutics that improve patients’ health and well-being. The company’s therapeutic solutions include monoclonal antibody biosimilars such as Remsima(Infliximab), Herzuma(Trastuzumab), Truxima(Rituximab), Remsima SC(Infliximab), Yuflyma(Adalimumab), and Vegzelma(Bevacizumab).